STERIS plc (NYSE:STE) Shares Bought by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC grew its position in STERIS plc (NYSE:STE) by 0.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,567 shares of the medical equipment provider’s stock after purchasing an additional 150 shares during the period. Kavar Capital Partners Group LLC’s holdings in STERIS were worth $4,639,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of STE. West Coast Financial LLC lifted its stake in shares of STERIS by 2.8% during the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock worth $398,000 after purchasing an additional 45 shares in the last quarter. SkyView Investment Advisors LLC lifted its position in STERIS by 1.6% during the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after acquiring an additional 51 shares in the last quarter. Park Edge Advisors LLC boosted its holdings in STERIS by 1.1% in the 4th quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock worth $958,000 after acquiring an additional 51 shares during the period. Central Pacific Bank Trust Division grew its position in STERIS by 65.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 76 shares in the last quarter. Finally, Metis Global Partners LLC raised its stake in shares of STERIS by 1.6% during the third quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after purchasing an additional 84 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Down 0.1 %

Shares of STERIS stock opened at $216.88 on Monday. The business has a 50-day moving average price of $211.46 and a 200 day moving average price of $224.77. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The firm has a market cap of $21.41 billion, a P/E ratio of 49.52 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.03 EPS. On average, sell-side analysts forecast that STERIS plc will post 9.11 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were issued a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. The ex-dividend date of this dividend was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is 52.05%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on STE shares. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Stephens reiterated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research note on Thursday, November 7th. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $262.50.

Insider Buying and Selling

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.14% of the stock is owned by company insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.